With the aim to generate improved translational human tauopathy models, we used ZFN technology to introduce the FTDP-17-associated MAPT IVS10+16 and P301S mutations into commercially available control hiPSCs (iPSC0028) from Sigma. This evidence concerns the gene MAPT and tauopathy.